CLAVAMOX Comprimé (à mâcher)

Land: Canada

Språk: fransk

Kilde: Health Canada

Aktiv ingrediens:

Amoxicilline (Trihydrate d'amoxicilline); Acide clavulanique (Clavulinate potassique)

Tilgjengelig fra:

ZOETIS CANADA INC

Dosering :

200MG; 50MG

Legemiddelform:

Comprimé (à mâcher)

Sammensetning:

Amoxicilline (Trihydrate d'amoxicilline) 200MG; Acide clavulanique (Clavulinate potassique) 50MG

Administreringsrute:

Orale

Enheter i pakken:

15G/50G

Resept typen:

Prescription

Terapeutisk gruppe:

Chats; Chiens

Produkt oppsummering:

Numéro de groupe d'ingrédients actifs (GIA) :0234720007

Autorisasjon status:

APPROUVÉ

Autorisasjon dato:

2019-06-19

Informasjon til brukeren

CLAVAMOX chewable tablets
Zoetis version January 28, 2020
LEAFLET
DIN 02489473
DIN 02489481
DIN 02489503
DIN 02489511
CLAVAMOX
®
_amoxicillin and clavulanate potassium chewable tablets _
_ _
Veterinary Use Only
DESCRIPTION: CLAVAMOX
®
(amoxicillin and clavulanate potassium_ _chewable
tablets) is an orally administered formulation comprised of the
broad-spectrum antibiotic
amoxicillin (as amoxicillin trihydrate) and the β-lactamase inhibitor
clavulanic acid (as
clavulanate potassium).
MEDICINAL INGREDIENTS:
-
Each 62.5 mg chewable tablet strength contains 50 mg amoxicillin (as
amoxicillin
trihydrate) and 12.5 mg clavulanic acid (as clavulanate potassium).
-
Each 125 mg chewable tablet strength contains 100 mg amoxicillin (as
amoxicillin
trihydrate) and 25 mg clavulanic acid (as clavulanate potassium).
-
Each 250 mg chewable tablet strength contains 200 mg amoxicillin (as
amoxicillin
trihydrate) and 50 mg clavulanic acid (as clavulanate potassium).
-
Each 375 mg chewable tablet strength contains 300 mg amoxicillin (as
amoxicillin
trihydrate) and 75 mg clavulanic acid (as clavulanate potassium).
INDICATIONS: CLAVAMOX chewable tablets are indicated for the treatment
of:
DOGS:
_Skin and Soft Tissue Infections _such as wounds, abscesses,
cellulitis, superficial/juvenile
and deep pyoderma due to susceptible strains of the following
bacteria:
• β-lactamase-producing _Staphylococcus aureus _
• non- β-lactamase-producing _Staphylococcus aureus _
• _Staphylococcus _spp., _Streptococcus _spp., and _E. coli _
_Urinary Tract Infections _(cystitis) due to susceptible strains of
_E. coli_.
_Gingivitis associated with periodontal infections _due to susceptible
strains of aerobic and
anaerobic bacteria.
CATS: _Skin and Soft Tissue Infections _such as wounds, abscesses, and
cellulitis/dermatitis due to susceptible strains of the following
bacteria:
• β-lactamase-producing _Staphylococcus aureus _
• non- β-lactamase-producing _Staphylococcus aureus _
• _Staphylococcus _spp., _Streptococcus _spp., _E. coli_, and
_P